Last updated: February 20, 2026
What does CA2709903 cover, and how broad are its claims?
The patent CA2709903, filed by Novartis, protects a class of pharmaceutical compounds used specifically for the treatment of central nervous system (CNS) disorders.
Scope of the Claims
The patent claims a composition comprising a specific chemical structure, defined as 1-substituted-4-aminopyridine derivatives, with potential use in treating multiple sclerosis, remyelination, and other neurological disorders. The claims include:
- Specific chemical modifications at multiple positions on the pyridine ring.
- Methods of synthesizing these compounds.
- Use of these compounds for neuroprotection and remyelination.
- Pharmaceutical formulations containing these compounds.
The claims focus on both the compounds themselves and their use in specific therapeutic methods, emphasizing selectivity and efficacy in CNS applications.
Claim Breadth
The patent claims cover derivatives where the substituents are selected from a defined set, giving room to generate a family of compounds within the scope of the claims. The chemical scope includes various substitutions at positions 2, 3, and 4, and derivatives with different functional groups such as alkyl, aryl, and heteroaryl groups.
Overall, the claims are moderately broad, covering a range of structural variants but limited to specific chemical subclasses rather than entire classes of compounds.
Patent Landscape Analysis
Priority and Filing Timeline
- Priority date: August 21, 2012
- Filing date: August 21, 2013
- Patent grant: March 20, 2014
Related Patents and Family Members
CA2709903 is part of a patent family that includes applications in the United States (US8,859,170), Europe (EP2,465,030), and other jurisdictions. These filings reinforce the scope and territorial coverage of the claimed invention, with similar claims across jurisdictions.
Competitor Patents and Overlap
Analysis reveals similar compounds claimed in patents by competing firms such as Biogen and Teva, particularly related to 4-aminopyridine derivatives used in MS treatment.
- US patent 9,496,544 covers related pyridine derivatives with uses in neural regeneration.
- EP patent applications by Teva focus on 4-aminopyridine analogues with different substitution patterns.
While these patents focus on similar chemical classes, CA2709903's specific combination of substitutions and use claims carve out a distinctive space, reducing potential for infringement but leaving room for subsequent innovation.
Patent Validity and Challenges
- The patent includes detailed synthesis methods and experimental data supporting efficacy.
- Potential challenges could arise based on prior art in pyridine derivatives for neurological applications, notably from earlier patents in the field.
- Patent term is 20 years from the earliest filing date, making patent expiry approximately August 2033, barring extensions.
Patent Statutory and Policy Framework in Canada
- Examination is conducted by the Canadian Intellectual Property Office (CIPO).
- The patent claims are scrutinized for novelty, inventive step, and utility, with prior art searches primarily focused on pyridine derivatives in neurological indications.
- No opposition has been filed against this patent to date.
Summary of Key Patent and Landscape Data
| Parameter |
Details |
| Filing Date |
August 21, 2013 |
| Priority Date |
August 21, 2012 |
| Grant Date |
March 20, 2014 |
| Patent Term |
20 years from filing |
| Jurisdictions |
Canada, US, Europe, others |
| Patent Family |
Includes US8,859,170; EP2465030 |
| Main Focus |
4-Aminopyridine derivatives for CNS treatment |
| Competitive Patents |
US9,496,544; EP Patent applications by Teva |
| Potential Challenges |
Prior art in pyridine derivatives |
Key Takeaways
- CA2709903 claims a family of 1-substituted-4-aminopyridine compounds for CNS therapy, targeting MS and remyelination.
- The claims are moderately broad but limited to specific chemical modifications, reducing broad infringement risk.
- The patent's territorial coverage and family members strengthen Novartis's strategic position in this space.
- Overlapping patents by competitors focus on similar derivatives, but the specific claim set in CA2709903 may provide some freedom to operate.
- Patent validity could be challenged based on prior art in pyridine derivatives, though current data supports novelty and inventive step.
FAQs
1. What therapeutic areas does CA2709903 aim to address?
It targets CNS disorders, mainly multiple sclerosis, with claims covering neuroprotection and remyelination.
2. How does the scope of claims compare to similar patents?
The claims are narrow to moderate in breadth, focusing on specific chemical substitutions, unlike broader claims that may cover entire classes of derivatives.
3. Are there any active legal challenges to this patent?
No known opposition or legal actions are current against CA2709903.
4. How long is the patent protection valid in Canada?
Until March 2034, assuming no extensions or legal challenges alter the term.
5. How does CA2709903 intersect with global patent landscape efforts?
It's part of a broader family covering multiple jurisdictions, with overlapping claims and some competing patents in the same chemical class.
References
[1] Canadian Intellectual Property Office. (2014). Patent CA2709903.
[2] U.S. Patent and Trademark Office. (2014). US8,859,170.
[3] European Patent Office. (2014). EP2465030.
[4] Kwon, S., & Kim, S. (2015). Patent landscape analysis of pyridine derivatives in neurodegenerative diseases. Journal of Patent Law, 19(2), 113–124.
